NCT03181789View on ClinicalTrials.gov

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 18, 2017

Primary Completion Date

October 25, 2019

Study Completion Date

April 29, 2020

Conditions
HIV Infections
Interventions
BIOLOGICAL

p24CE1/2 pDNA Vaccine

Administered bilaterally using the Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device

BIOLOGICAL

p55^gag pDNA Vaccine

Administered bilaterally using the TDS-IM EP device

BIOLOGICAL

IL-12 pDNA Adjuvant

Administered bilaterally using the TDS-IM EP device

BIOLOGICAL

Placebo

Administered bilaterally using the TDS-IM EP device

DEVICE

Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device

The TDS-IM EP device will be used to administer study product(s).

Trial Locations (3)

30030

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

44106

Case Clinical Research Site, Cleveland

94143

Bridge HIV CRS, San Francisco

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03181789 - Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA | Biotech Hunter | Biotech Hunter